Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
27.7 HKD | -0.18% | -2.64% | 0.00% |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales 1 | 21.35 | 9.662 | 14.75 |
EBITDA 1 | -155.6 | -295.5 | -484.1 |
EBIT 1 | -179.3 | -324.2 | -514.2 |
Operating Margin | -840.05% | -3,354.95% | -3,486.18% |
Earnings before Tax (EBT) 1 | -426.5 | -312.4 | -521.3 |
Net income 1 | -411 | -298.2 | -507.7 |
Net margin | -1,925.33% | -3,086.22% | -3,442.13% |
EPS 2 | -2.566 | -1.677 | -2.469 |
Free Cash Flow | - | -152.5 | -125.3 |
FCF margin | - | -1,578.81% | -849.35% |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 11/03/24 | 11/03/24 | 26/04/24 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | - | - | - |
Net Cash position 1 | 330 | 319 | 31.2 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | -153 | -125 |
ROE (net income / shareholders' equity) | - | -45.7% | -108% |
ROA (Net income/ Total Assets) | - | -19.3% | -35.1% |
Assets 1 | - | 1,547 | 1,446 |
Book Value Per Share 2 | 4.030 | 3.550 | 1.400 |
Cash Flow per Share 2 | 1.310 | 1.180 | 1.030 |
Capex 1 | 58 | 20.1 | 7.87 |
Capex / Sales | 271.56% | 208.18% | 53.38% |
Announcement Date | 11/03/24 | 11/03/24 | 26/04/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 801M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- 2509 Stock
- Financials Qyuns Therapeutics Co., Ltd.